State of New Jersey Common Pension Fund D Acquires 5,701 Shares of Twist Bioscience Co. (NASDAQ:TWST)

State of New Jersey Common Pension Fund D grew its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 12.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 50,803 shares of the company's stock after acquiring an additional 5,701 shares during the period. State of New Jersey Common Pension Fund D owned 0.09% of Twist Bioscience worth $2,361,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in TWST. Wilmington Savings Fund Society FSB acquired a new stake in shares of Twist Bioscience in the third quarter valued at approximately $34,000. Van ECK Associates Corp grew its position in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after acquiring an additional 267 shares during the last quarter. Signaturefd LLC raised its stake in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after acquiring an additional 306 shares in the last quarter. Beaird Harris Wealth Management LLC acquired a new stake in shares of Twist Bioscience in the 3rd quarter valued at approximately $95,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock valued at $98,000 after purchasing an additional 381 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on TWST shares. Robert W. Baird lifted their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 4th. JPMorgan Chase & Co. increased their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research report on Tuesday, February 4th. Wolfe Research started coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 price target on the stock. Barclays lowered their price objective on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a research report on Tuesday, November 19th. Finally, Scotiabank raised their target price on Twist Bioscience from $54.00 to $62.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience presently has an average rating of "Moderate Buy" and a consensus target price of $53.80.

Twist Bioscience Stock Down 8.4 %

NASDAQ:TWST traded down $3.77 on Friday, hitting $41.31. The stock had a trading volume of 1,566,739 shares, compared to its average volume of 872,724. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The business's fifty day moving average is $48.10 and its 200 day moving average is $45.75. The company has a market cap of $2.46 billion, a PE ratio of -12.22 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Twist Bioscience's quarterly revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.75) earnings per share. On average, equities research analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Dennis Cho sold 806 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $39,776.10. Following the sale, the insider now directly owns 112,221 shares in the company, valued at approximately $5,538,106.35. The trade was a 0.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Adam Laponis sold 5,886 shares of the business's stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the sale, the chief financial officer now directly owns 110,096 shares in the company, valued at approximately $4,762,752.96. This trade represents a 5.07 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 37,180 shares of company stock valued at $1,821,971. Company insiders own 3.01% of the company's stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.